Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.01
4% from low
Exchange
OTC Link
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | $0 | $42.0M | $1.4M | $3.6M | $0 |
| Cost of revenue | $307.0K | $0 | $24.0K | $53.0K | $111.0K |
| Gross profit | −$307.0K | $42.0M | $1.4M | $3.5M | −$111.0K |
| Gross margin | — | 100.0% | 98.3% | 98.5% | — |
| R&D | $23.6M | $21.8M | $20.0M | $23.3M | $22.9M |
| Operating income | −$28.6M | $15.8M | −$33.3M | −$32.4M | −$33.8M |
| EBITDA | −$28.1M | $16.1M | $17.6M | −$20.4M | −$32.8M |
| Net income | −$29.7M | $14.2M | $15.8M | −$12.9M | −$35.8M |
| Net margin | — | 33.8% | 1104.8% | -363.8% | — |
| EPS (diluted) | -539.08 | 0.10 | 9.78 | -7.85 | -16.37 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-21.00 | $-21.00–$-21.00 | 1 |
| 2027 | $51M | $-17.50 | $-17.50–$-17.50 | 1 |
Forward consensus · source: Financial Modeling Prep
EFFECTOR THERAPUTCS INC
No one on the platform currently holds EFTR.
No tracked institution reports a position in EFTR as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-01-12 | 1-for-25reverse |
No one on the platform has traded EFTR yet.
| $1010 |
| — |
| IMVIFIMV Inc. | $0.00 | +0.00% | $23423 | — |
| LITHBioELife Corp. | $0.00 | +0.00% | $941 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $EFTR (eFFECTOR Therapeutics, Inc.) based on financial data and reported results. #EFTR #eFFECTOR
View on StockTwits ↗$LYRA There is a reason why Sabby entered with 9.90% long position to short right after that corporate update! and it’s definitely not for good reason! Reminds me of cash rich $EFTR which was taken to 0 by the mgmt by spending all the cash! $LYRA mgmt seems to have similar intention!
View on StockTwits ↗@Zkoko_Bio it can be very risky. I've seen, a lot of Bio nose dive after readouts or trials results and NO, thanks save pethaps P3 trials after doing your DD thourougly on P2 results. Last exemple i always keep in mind $EFTR (thanks Universe, i didn't buy. I had a very bad hunch because they did a RS just before, with a very suspect ratio 1 for 25)
View on StockTwits ↗$EFTR Today’s setup looks strong. Stay disciplined. Focus on the process. Expect positive outcomes. Keep sharp and aim for success!
View on StockTwits ↗$EFTR stockholders filed a claim against eFFECTOR Therapeutics for allegedly misleading investors ahead of its 2024 stock offering and abruptly announcing a full wind-down months later. You can join this case to be notified about any new information: https://11th.com/cases/effector-investor-case
View on StockTwits ↗$EFTR stockholders filed a claim against eFFECTOR Therapeutics for misleading them about its clinical progress, financial stability, and future operations ahead of its 2024 stock offering. You can join this case to be notified about potential recovery: https://11th.com/cases/effector-investor-case
View on StockTwits ↗$EFTR Zotatifin looking promising in breast cancer trials. Watching closely for next clinical updates. Might nibble on small position if more positive data comes out. strong article: https://beyondspx.com/article/effector-therapeutics-inc-eftr-pioneering-a-new-class-of-oncology-drugs
View on StockTwits ↗$LXRX overall good news... stable growth, should enter a phase of rapid sustainable growth... $IBRX $EFTR $GRTX seems like $LXRX will grow soon and will have profitability soon... very good job!
View on StockTwits ↗@sixmilliondollarman you meant you're a BS pump clown, tell me how much $$$ did you lose with $EFTR and with $SRZN ? position trading with biotech that might never get a FDA approval ? LMAO, you're just a bag holder that has a fetish for turds, like this $GLTO
View on StockTwits ↗$ATXI this company is dead, they will wind down the business like $EFTR has done. Mote likely say goodbye to your bags. SCAM
View on StockTwits ↗$EFTR why even this is active? Is there still any hope to have some company buy their research and continue it? Anyone?
View on StockTwits ↗@Wallst45 be careful with this guy pump and dump is his game remember $EFTR $XFOR $PDSB to name a few
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.